TRYPTASE OF ORAL LIQUID AND IgE-ANTIBODIES AS A MARKER OF ALLERGIC INFLAMMATION IN THE ORAL MUCOSA

The goal of present study was to determine the levels of mast cell tryptase (MCT) in whole saliva, and blood serum IgE antibodies in patients with intolerance for dental prosthetic materials (IDM) before and after removal of prosthetic constructs. We have conducted examination of the patients suffering from the IDM symptoms, who were divided into 2 groups depending on the time span between the end of prosthetic treatment and emergence of pathological symptoms: group 1 (n = 19), 1 to 14 days (symptoms emerged immediately after treatment); group 2, (n = 18), IDM symptoms occuring 6 months to 5 years later; group 3 (n = 16), controls without complaints for IDM. Whole saliva (WS) samples were collected before removal of prosthetic constructs and 1 month later. In group 1, salivary MCT was detected in 16 subjects (84.2%) before removal of prosthetic constructs, while 1 month after MCT not detectable in saliva (p < 0.001). Salivary MCT in control group was not detected both before and after removal of prosthetic constructions. Hence, mast cell tryptase in whole saliva could be a diagnostic marker for intolerance to dental materials. In group 1 of the patients, we detected IgE antibodies to Ni-HSA in 78.9% of patients, IgE antibodies to Cr-HSA in 68.4% of patients and IgE to Co-HSA in 52.6% of patients. Salivary MCT levels strongly correlated with IgE levels to Ni-HSA (R_spearman = 0.9; p < 0.05), showing moderate correlation with Cr-HSA (R_spearman = 0.7; p < 0.05). The data obtained suggest some prevalence of immediate type immune reaction against dental materials. Notable local increase of MCT level could be an important diagnostic marker of local inflammatory process initiation. MCT in whole saliva was found only in 3 patients (16.7%) from group 2; those had IgE antibodies to metal ions in blood serum, thus indicating IgE-dependent reaction type. Other patients from group 2 were likely to develop a different type of allergic reaction, e. g. delayed or granulocyte-mediated response. To perform reliable diagnostics of allergy to the components of dental materials, it is reasonable to measure salivary MCT before and after removal of prosthetic constructs. Salivary MCT level monitoring allows to confirm a role of prosthetic constructs in IDM emergence, and a need for their replacement.

1. Карпук Н.А., Карпук И.Ю. Диагностика аллергии на металлические изделия в реакции аллергениндуцированного повреждения лейкоцитов // Медицинские новости, 2012. № 6. С. 75-76. [Karpuk N.A., Karpuk I.Yu. Diagnosis of allergy to metal products in the reaction of allergenic-induced leukocyte damage. Meditsinskie novosti = Medical News, 2012, no. 6, pp. 75-76. (In Russ.)]

2. Новиков Д.К., Новиков П.Д. Клиническая иммунопатология: руководство. М.: Медицинская литература, 2009. 464 с. [Novikov D.K., Novikov P.D. Clinical immunopathology: a guide]. Moscow: Medical Literature, 2009. 464 p.

3. Новиков Д.К., Сергеев Ю.В., Новиков П.Д. Лекарственная аллергия. М.: Национальная академия микологии, 2001. 313 с. [Novikov D.K., Sergeev Yu.V., Novikov P.D. Medicinal allergy]. Moscow: National Academy of Mycology, 2001. 313 p. (In Russ.)]

4. Новиков П.Д., Новиков Д.К., Титова Н.Д. Диагностика аллергии и гиперчувствительности: ведущее значение клеточных методов // Иммунопатология, аллергология, инфектология, 2016. № 4. С. 25-39. [Novikov P.D., Novikov D.K., Titova N.D. Diagnosis of allergy and hypersensitivity: the leading importance of cellular methods. Immunopatologiya, allergologiya, infektologiya = Immunopathology, Allergology, Infectology, 2016, no. 4, pp. 25-39. (In Russ.)]

5. Blank U. The mechanisms of exocytosis in mast cells. Adv. Exp. Med. Biol., 2011, Vol. 716, pp. 107-122.

6. Chen S., Mu D., Cui M., Ren C., Zhang S., Guo L., Gao W. Dynamic changes and clinical significance of serum tryptase levels in STEMI patients treated with primary PCI. Biomarkers, 2014, Vol. 19, no. 7, pp. 620-624.

7. Jogie-Brahim S., Min H.K., Fukuoka Y., Xia H.Z., Schwartz L.B. Expression of alpha-tryptase and beta-tryptase by human basophils. J. Allergy Clin. Immunol., 2004, Vol. 113, no. 6, pp. 1086-1092.

8. Kumar V., Sharma A. Mast cells: emerging sentinel innate immune cells with diverse role in immunity. Mol. Immunol., 2010, Vol. 48, no. 1-3, pp. 14-25.

9. Lorentz A., Baumann A., Vitte J., Blank U. The SNARE machinery in mast cell secretion. Front. Immunol., 2012, Vol. 3, p. 143.

10. Lundequist A., Pejler G. Biological implications of preformed mast cell mediators. Cell. Mol. Life Sci., 2011, Vol. 68, no. 6, pp. 965-975.

11. Niedoszytko M., Chełmińska M., Chełmiński K., Knopińska-Posłuszny W., Gruchała-Niedoszytko M., Jassem E. Late-phase allergic reaction in nasal provocation with fungal allergens. Allergy Asthma Proc., 2008, Vol. 29, no. 1, pp. 35-39.

12. Ruëff F., Friedl T., Arnold A., Kramer M., Przybilla B. Release of mast cell tryptase into saliva: a tool to diagnose food allergy by a mucosal challenge test? Int. Arch. Allergy Immunol., 2011, Vol. 155, no. 3, pp. 282-288.

13. Sargur R., Cowley D., Murng S., Wild G., Green K., Shrimpton A., Egner W. Raised tryptase without anaphylaxis or mastocytosis: heterophilic antibody interference in the serum tryptase assay. Clin. Exp. Immunol., 2011, Vol. 163, no. 339-345.

14. Schliemann S., Seyfarth F., Hipler U.C., Elsner P. Impact of age and heterophilic interference on basal serum tryptase, a risk indication for anaphylaxis, in 1092 dermatology patients. Acta Derm. Venereol., 2012, Vol. 92, no. 5, pp. 484-489.

15. St. John A.L., Abraham S.N. Innate immunity and its regulation by mast cells. J. Immunol., 2013, Vol. 190, no. 9, pp. 4458-4463.

16. Trivedi N.N., Caughey G.G. Mast cell peptidases. Chameleons ofinnate immunity and host defense. Am. J. Respir. Cell Mol. Biol., 2010, Vol. 42, no. 3, pp. 257-267.

17. Valent P. Mast cell activation syndromes: definition and classification. Allergy, 2013, Vol. 68, no. 4, pp. 417-424.

18. Valent P., Akin C., Arock M., Brockow K., Butterfield J.H., Carter M.C., Castells M., Escribano L., Hartmann K., Lieberman P., Nedoszytko B., Orfao A., Schwartz L.B., Sotlar K., Sperr W.R., Triggiani M., Valenta R., Horny H.P., Metcalfe D.D. Definitions, criteria and global classi- fications of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int. Arch. Allergy Clin. Immunol., 2012, Vol. 157, no. 3, pp. 215-225.

19. Vitte J. Human mast cell tryptase in biology and medicine. Mol. Immunol., 2015, Vol. 63, no. 1, pp. 18-24.

20. Voehringer D. Protective and pathological roles of mast cells and basophils. Nat. Rev. Immunol., 2013, Vol. 13, pp. 362-375.